Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Scandion Oncology, Audiocast with teleconference, Q3'24

By Inderes11/11/2024, 8:00 AM
Scandion Oncology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Francois Martelet
00:00 - 05:24

Good morning, everyone, and thank you for attending this quarterly call for 2024. Uh, could I have the next slide, please? Which is the disclaimer. The classical disclaimer is that we will not go through the next slide. So together with me, we have Johnny Stilou, our CFO, and I will quickly go through the clinical updates. Then Johnny will go through the financial performance, and then I will update you about our partnering activities. Next slide, please. Yes. All right. So you can see us. Next slide. Right. So, as most of you likely know, we are involved in Colorectal Cancer. We are a drug resistance company. One of the first companies actually in this setting. And we have, over the last few years, engaged in a program called CORIST. And, with our compound, our lead compound, SCO-101, which is a small molecule combined with FOLFIRI, we've advanced from phase one to phase two, and now we are in phase two A. We are certainly expecting the final data to be released early. In 2025, we released the top-line data, which are positive phase 2A data. And we will be releasing the final data analysis early in 2025. So, for colorectal cancer, this pertains to the CORIST program. And I will go into more details later on. PANTAX is our clinical trial in pancreatic cancer. This is a phase 1B. We have released the data earlier this year that show good tolerability, good safety with a combination of nab-paclitaxel and gemcitabine and, of course, SCO-101. At the same time, you know, we engaged earlier in gastric cancer and have been able to release some good preclinical data for this indication. Therefore, we are ready to engage in a phase 1B2A. At the same time, mainly due to cost constraints, we have not been able to continue the preclinical development program with SCO-201. But this is certainly an asset that could also potentially be used in other indications beyond oncology, like HIV, and that asset is currently on hold from a preclinical development perspective. Should I have the next slide, please? Right. So here are a bit more details about CORIST. So we've been able to release the top-line data earlier in the year. We've been able to demonstrate a good safety and tolerability profile. Something which is very important in oncology is, of course, partial responses. And in the last cohort where we've been able to demonstrate our MTD, we have got two PRs. And this is extremely encouraging for us and for the patients. Of course, at the same time, we've been able to show a significant overall survival, which is in the range of 8 to 10 months. And also, if we are selecting a subgroup of patients expressing one type of UGT1A1, then we've been able to increase the overall survival up to 13 months, which is significant. I know, of course, that this is based on a limited set of patients, but at least we have to start somewhere. And obviously, this can only be encouraging for the future development of our clinical trial. So the conclusion is that we've been able to achieve an MTD (maximum tolerated dose) for the four-day schedule using SCO-101 in combination with FOLFIRI, meaning that we have 50% oenothera dosage and 100% Leucovorin and 5-FU. And then the result is that we have an MTD at 250 mg per day of SCO-101. So altogether, this is extremely encouraging for continuing the development of our clinical development plan for colorectal cancer with SCO-101. Next slide, please. So this is for Johnny. Johnny, please go ahead.

Johnny Stilou
05:24 - 07:19

Thank you. Yes, this is the financial overview. And as you can see, the third quarter of 2024 ended with a net loss of 6.7 million Danish kroner. This is compared to the same quarter last year, where we had a net loss of 10.1 million Danish kroner. The reduction in loss and cost is driven by reduced clinical costs, as our two clinical programs have been downscaled. Our cash position at the end of September, the end of the quarter, ended with a balance of 14.8 million Danish kroner. Now, with this number. Bear in mind that we have a tax credit due of 5.5 million Danish kroner, which we receive annually due to our clinical costs, clinical programs. And this money, 5.5 million Danish kroner, we will receive for this year later in this month, in November. But as of the end of September, we had 14.8 million Danish kroner. With that cash position, we are able to fund the operation into the fourth quarter of next year, 2025. And here on the next slide, you can see graphically that our cost is being reduced quarter over quarter. And we expect the same reduction in quarter-over-quarter costs to continue into 2025, which is why, as just mentioned, our current cash position will sustain us into the fourth quarter of 2025. With that, I will hand the word back to Francois.

Francois Martelet
07:20 - 10:19

Thank you, Johnny. So, if I could summarize where we stand now. As you know, we are a drug resistance company. We are one of the first movers in this direction. And with our SCO-101, potentially we have a first-in-class drug inhibitor. And we are targeting two targets, CPG2 and UGT1A1, as you know. So we are really a precision anti-cancer drug company. We've been able to demonstrate good data from a phase 2A in colorectal cancer. Also, some good data in phase 1B in pancreatic cancer. And certainly, our compound has broad commercial potential not only in those indications but also in others that could be further developed depending on our financial position. Financially speaking, we've been able to control costs very drastically. And as Johnny said, we are able to finance the company into Q4 2025. Obviously, what's next? As most of you have understood, we are now in the middle of the development process for colorectal cancer. Having achieved good phase two. Having achieved good phase two A, so now we need to move the pipeline towards phase 2B/3. In order to do that, we certainly need additional funding, and performing a phase 2B3 in colorectal cancer requires hundreds of patients. Therefore, from a financial perspective, we need to have a partner, given the market conditions, given where we stand as a publicly listed company. A partner is absolutely needed in order to continue this development program. And this is exactly what I am focusing all my efforts on, together with Johnny and our CMO and our CSO. And on that side, I'm sure you will appreciate some confidential information that I cannot disclose, but be absolutely sure that we are doing our utmost to find a partner. And of course, we will be releasing good news whenever available. And I will not say more about that. But again, rest assured that our commitment is 100% towards these development activities. Uh, next slide please. And this will conclude our brief presentation today, and I am open to any questions you may have. Slide set today, and I am open to any questions you may have. Back to you. Operator, please.

Operator
10:21 - 10:54

Thank you. If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. We'll have a brief pause while questions are being registered. There seem to be no questions. So, I hand the word back to you, Francois and Johnny.

Francois Martelet
10:57 - 11:13

Thank you. Thank you to the audience for listening to us today on this important but short call. And again, we will be updating the market as soon as we have news on the business development side. Thank you very much. And have a good day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…